Tomasello Shawn 4

What Happened

• Shawn Tomasello, a director of 4D Molecular Therapeutics, received a grant of 50,000 derivative shares (reported as $0.00) on June 17, 2026 under the company’s non-employee director compensation program. This was an award/grant of a stock option-type derivative — no cash was paid at grant and there is no immediate cash value.

Key Details

• Transaction date: 2026-06-17; Filing date (Form 4): 2026-06-18 (appears timely).
• Transaction type/code: A — Grant/award (derivative). Reported price: $0.00 for 50,000 shares.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: (1) Award was automatically granted under the non-employee director compensation program. (2) Vesting: 1/3 vests on June 17, 2027, then equal monthly installments until fully vested on June 17, 2029; the options also vest in full upon a Change in Control per the 2020 Incentive Award Plan.
• No indication of a sale, exercise, or tax-withholding event in this filing.

Context

• This is a grant of a derivative award (stock option-style) rather than an open-market purchase or sale. Such grants are common for directors as part of compensation and do not by themselves signal buying or selling intent. The award vests over time (or on a change in control), meaning Tomasello must remain a director (or a change in control must occur) before the award becomes exercisable/realized.